In the case of TPT in cisplatin-resistant epithelial ovarian cancer, response rates are low (10–15%) due to decreased expression of Topo I and overexpression of ABC transporters such as ABCB1/P-gp and ABCG2/BCRP, which actively expel the drug and promote cross-resistance to multiple chemotherapeutic agents [142,143,144,145,146,147,148,149]. Here, ABCG2 is linked to ovarian carcinoma.